Ladinin (Ciprofloxacin)

Ciprofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By inhibiting these targets, the drug prevents bacterial cells from dividing and repairing their DNA, leading to bacterial cell death and resolution of the infection.

The dosage of Ladinin is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and other clinical factors. Specific dosing regimens are not provided here and should follow the prescriber’s order and local guidelines.

The pregnancy category for ciprofloxacin is not definitively established. Use during pregnancy or lactation is only recommended when the potential benefits outweigh the possible risks to the fetus or infant, and it should be decided by the treating physician.

To request Ladinin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling for the IV product) and necessary import documentation.

Ladinin (ciprofloxacin) offers broad‑spectrum activity against many Gram‑negative and some Gram‑positive bacteria, with excellent tissue penetration and the convenience of once‑daily IV dosing. Compared with beta‑lactam antibiotics, it may be more effective against resistant Pseudomonas and certain atypical pathogens, but it carries specific risks such as tendon injury and QT prolongation that must be weighed.

Ladinin should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use and follow aseptic techniques during preparation and administration to maintain sterility.

Ladinin is given as an intravenous infusion. The exact infusion rate and duration are set by the prescribing clinician, typically over 30 minutes to 1 hour, and should be administered under medical supervision with appropriate monitoring for adverse reactions.

Serious risks include tendon rupture or tendinitis, Clostridioides difficile‑associated colitis, QT interval prolongation leading to arrhythmias, severe allergic reactions such as anaphylaxis, and central nervous system effects like seizures. Patients should be monitored closely for these events, especially if they have pre‑existing risk factors.

Ladinin should be avoided in patients with a known hypersensitivity to ciprofloxacin or other fluoroquinolones, those with a history of tendon disorders who are also taking corticosteroids, individuals with significant QT prolongation or uncontrolled electrolyte abnormalities, and patients with severe renal impairment unless dose adjustments are made.